Enza Piccolo

Via Della Colonnetta 50/A
Chieti, 66100, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma.

Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma.

Journal: Cancers

Published: August 29, 2020

Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity - implications for mechanistic pharmacokinetics modeling.

Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity - implications for mechanistic pharmacokinetics modeling.

Journal: Scientific reports

Published: March 20, 2019

Secreted Gal-3BP is a novel promising target for non-internalizing Antibody-Drug Conjugates.

Secreted Gal-3BP is a novel promising target for non-internalizing Antibody-Drug Conjugates.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: October 16, 2018

Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma.

Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma.

Journal: Oncotarget

Published: May 11, 2017

Prognostic relevance of LGALS3BP in human colorectal carcinoma.

Prognostic relevance of LGALS3BP in human colorectal carcinoma.

Journal: Journal of translational medicine

Published: May 10, 2015

Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody.

Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody.

Journal: Molecular cancer therapeutics

Published: February 21, 2014

EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo.

EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo.

Journal: Translational oncology

Published: June 17, 2013

Tumor-derived microvesicles: the metastasomes.

Tumor-derived microvesicles: the metastasomes.

Journal: Medical hypotheses

Published: June 01, 2012

LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis.

LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis.

Journal: Journal of molecular medicine (Berlin, Germany)

Published: May 03, 2012

Showing 1-9 of 9

Last Updated: 09/26/2026